This process remodels the TIME and enhances the cytotoxic T‐cell‐mediated tumor immunotherapeutic effect, thereby overcoming resistance to anti‐PD‐1 therapy in residual tumor models of hepatocellular carcinoma following insufficient radiofrequency ablation. The gene discussed is PDCD1; the disease is neoplasm.